Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 15, 2021 - Issue 4
Submit an article Journal homepage
327
Views
35
CrossRef citations to date
0
Altmetric
Perspective

A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD

Yusuf Yilmaza Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey;b Liver Research Unit, Institute of Gastroenterology, Marmara University, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4518-5283View further author information
ORCID Icon,
Christopher D. Byrnec National Institute for Health Research, Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK;d School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UKORCID Iconhttps://orcid.org/0000-0001-6322-7753View further author information
ORCID Icon &
Giovanni Mussoe HUMANITAS Gradenigo Hospital; Laboratory of Diabetology and Metabolism, Department of Medical Sciences, Città della Salute, University of Turin, Turin, ItalyORCID Iconhttps://orcid.org/0000-0002-8569-2872View further author information
ORCID Icon
Pages 345-352 | Received 31 Oct 2020, Accepted 02 Dec 2020, Published online: 09 Dec 2020

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Qian Gao, Lei Feng, Weiling Zhou, Xiaoli Li, Lanzi Yin & Yuan Wang. (2023) Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity 16, pages 2345-2354.
Read now
Lucia Brodosi, Francesca Marchignoli, Giulio Marchesini & Maria Letizia Petroni. (2022) Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. Expert Opinion on Pharmacotherapy 23:2, pages 149-153.
Read now
Yunlei Deng, Qianwen Zhao & Rong Gong. (2021) Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018. Diabetes, Metabolic Syndrome and Obesity 14, pages 1751-1761.
Read now
Alessandro Cherubini, Elia Casirati, Melissa Tomasi & Luca Valenti. (2021) PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opinion on Therapeutic Targets 25:12, pages 1033-1043.
Read now

Articles from other publishers (31)

Tian‐Lei Zheng, Jun‐Cheng Sha, Qian Deng, Shi Geng, Shu‐Yuan Xiao, Wen‐Jun Yang, Christopher D. Byrne, Giovanni Targher, Yang‐Yang Li, Xiang‐Xue Wang, Di Wu & Ming‐Hua Zheng. (2023) Object detection: A novel AI technology for the diagnosis of hepatocyte ballooning. Liver International.
Crossref
Yuka Hasegawa, Hiroshi Okada, Hanako Nakajima, Nobuko Kitagawa, Takuro Okamura, Saori Majima, Takafumi Senmaru, Emi Ushigome, Naoko Nakanishi, Yuki Nakahata, Akihiro Obora, Takao Kojima, Masahide Hamaguchi & Michiaki Fukui. (2023) Effects of Weight Loss on Metabolic Dysfunction‐Associated Fatty Liver Disease in Japanese People: NAGALA Study. Hepatology Research.
Crossref
Xin-Juan Huang, Man Yin, Bing-Qian Zhou, Xin-Yun Tan, Yuan-Qin Xia & Chun-Xiang Qin. (2023) Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors. World Journal of Hepatology 15:8, pages 985-1000.
Crossref
Mykhailo Buchynskyi, Valentyn Oksenych, Iryna Kamyshna, Sandor G. Vari & Aleksandr Kamyshnyi. (2023) Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis. Viruses 15:8, pages 1724.
Crossref
Mykhailo Buchynskyi, Iryna Kamyshna, Valentyn Oksenych, Nataliia Zavidniuk & Aleksandr Kamyshnyi. (2023) The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence. Viruses 15:5, pages 1072.
Crossref
Ji Yeon Lee, Minju An, Huijin Heo, Jeong-Yong Park, Junsoo Lee & Chang-Ho Kang. (2023) Limosilactobacillus fermentum MG4294 and Lactiplantibacillus plantarum MG5289 Ameliorates Nonalcoholic Fatty Liver Disease in High-Fat Diet-Induced Mice. Nutrients 15:8, pages 2005.
Crossref
Adina Mitrea, Ionela Mihaela Vladu, Maria Magdalena Rosu, Diana Clenciu, Eugen Mota & Maria Mota. 2023. Type 2 Diabetes - From Diagnosis to Effective Management [Working Title]. Type 2 Diabetes - From Diagnosis to Effective Management [Working Title].
Shreya C. Pal & Nahum Méndez-Sánchez. (2023) Screening for MAFLD: who, when and how?. Therapeutic Advances in Endocrinology and Metabolism 14, pages 204201882211456.
Crossref
Cristiane A. Villela Nogueira & Nathalie Carvalho Leite. 2023. The Diabetes Textbook. The Diabetes Textbook 261 270 .
Nahum Méndez‐Sánchez, Jian‐Gao Fan, Mohamed El‐Kassas & Marcos Girala. (2022) MAFLD : A quick fact check . Liver International 42:12, pages 2903-2906.
Crossref
Cheng Han Ng, Daniel Q. Huang & Mindie H. Nguyen. (2022) Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name. Clinical and Molecular Hepatology 28:4, pages 790-801.
Crossref
Concetta Mastromauro, Nella Polidori & Cosimo Giannini. (2022) Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes. Current Opinion in Pediatrics 34:4, pages 414-422.
Crossref
Yiwen ShiJiangao Fan. (2022) Therapeutic developments in metabolic dysfunction-associated fatty liver disease. Chinese Medical Journal 135:9, pages 1009-1018.
Crossref
Eda Kaya & Yusuf Yilmaz. (2021) Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver. Journal of Clinical and Translational Hepatology 10:2, pages 329-338.
Crossref
Costanza Renata Neri, Serena Scapaticci, Francesco Chiarelli & Cosimo Giannini. (2022) Liver Steatosis: A Marker of Metabolic Risk in Children. International Journal of Molecular Sciences 23:9, pages 4822.
Crossref
Ting-Yao Wang, Rui-Fang Wang, Zhi-Ying Bu, Giovanni Targher, Christopher D. Byrne, Dan-Qin Sun & Ming-Hua Zheng. (2022) Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nature Reviews Nephrology 18:4, pages 259-268.
Crossref
Yoshitaka Hashimoto, Masahide Hamaguchi, Takuro Okamura, Naoko Nakanishi, Akihiro Obora, Takao Kojima & Michiaki Fukui. (2021) Metabolic associated fatty liver disease is a risk factor for chronic kidney disease. Journal of Diabetes Investigation 13:2, pages 308-316.
Crossref
Mina Tharwat, MohammedA Medhat & Mohamed El-Kassas. (2022) The NAFLD–MAFLD debate through the lens of the Arab world. Saudi Journal of Gastroenterology 28:6, pages 413.
Crossref
饺饺 黄. (2022) Related Factors of Metabolic Associated Fatty Liver Disease. Advances in Clinical Medicine 12:01, pages 331-336.
Crossref
Eda Kaya & Yusuf Yilmaz. (2022) Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease. Therapeutic Advances in Endocrinology and Metabolism 13, pages 204201882211396.
Crossref
Qianqian Ma, Junzhao Ye, Congxiang Shao, Yansong Lin, Tingfeng Wu & Bihui Zhong. (2022) Metabolic benefits of changing sedentary lifestyles in nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Therapeutic Advances in Endocrinology and Metabolism 13, pages 204201882211224.
Crossref
Yanlan Xu, Xinyu Yang, Hua Bian & Mingfeng Xia. (2021) Metabolic dysfunction associated fatty liver disease and coronavirus disease 2019: clinical relationship and current management. Lipids in Health and Disease 20:1.
Crossref
Yunxia Zhu, Jun Xu, Xiaoyan Zhang, Yingying Ke, Guoxiang Fu & Qihao Guo. (2021) A low follicle-stimulating hormone level is a protective factor for non-alcoholic fatty liver disease in older men aged over 80. BMC Geriatrics 21:1.
Crossref
Shahinul Alam & Shah Mohammad Fahim. (2021) Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. World Journal of Hepatology 13:10, pages 1203-1207.
Crossref
Jiaye Liu, Chunyang Mu, Kewei Li, Han Luo, Yong Liu & Zhihui Li. (2021) Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis. International Journal of Public Health 66.
Crossref
Evangelia S. Makri, Antonis Goulas & Stergios A. Polyzos. (2021) Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease. European Journal of Pharmacology 907, pages 174272.
Crossref
Thaninee Prasoppokakorn, Panyavee Pitisuttithum & Sombat Treeprasertsuk. (2021) Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Journal of Clinical and Translational Hepatology 000:000, pages 000-000.
Crossref
Zahra Namkhah, Fatemeh Naeini, Alireza Ostadrahimi, Helda Tutunchi & Mohammad Javad Hosseinzadeh‐Attar. (2021) The association of the adipokine zinc‐alpha2‐glycoprotein with non‐alcoholic fatty liver disease and related risk factors: A comprehensive systematic review. International Journal of Clinical Practice 75:7.
Crossref
Qianqian Ma, Xianhua Liao, Congxiang Shao, Yansong Lin, Tingfeng Wu, Yanhong Sun, Shi-Ting Feng, Junzhao Ye & Bihui Zhong. (2021) Normalization of γ-glutamyl transferase levels is associated with better metabolic control in individuals with nonalcoholic fatty liver disease. BMC Gastroenterology 21:1.
Crossref
Mi Na Kim, Kyungdo Han, Juhwan Yoo, Yeonjung Ha, Young Eun Chon, Ju Ho Lee, Tracey G. Simon, Andrew T. Chan & Seong Gyu Hwang. (2021) Body weight variability and the risk of cardiovascular outcomes in patients with nonalcoholic fatty liver disease. Scientific Reports 11:1.
Crossref
Seong Hee Kang, Yuri Cho, Soung Won Jeong, Seung Up Kim & Jin-Woo Lee. (2021) From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?. Clinical and Molecular Hepatology 27:2, pages 257-269.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.